Enrique M. Ocio on Muck Rack

Enrique M. Ocio

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Enrique M.

Contact Enrique M., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

|
By Shaji Kumar Verified, Sundar Jagannath, Katja Weisel, Laura Rosiñol, Xavier Leleu, Meletios-Athanasios Dimopoulos, Efstathios Kastritis, David Siegel, Jorge Monge, Juan Du, Pedro Asensi Cantó, Jae Lee, Maria-Victoria Mateos, Borja Puertas, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Bladé, Shuji Ozaki, Meral Beksac, Fernando Escalante, Madhu Nagaraj, Rafla Hassan, Nicolle A. Bonar, Paul Spin, Mostafa Shokoohi, Di Wang, Kevin Hou, Michael West, Christian Hampp, Olivier Humblet, Alexander Breskin, James Harnett, Wenzhen Ge, Rachel Sobel, Jessica J. Jalbert, Karen Rodriguez Lorenc, Qiufei Ma, Brian Durie, Javier de la Rubia, Muhaimen Siddiqui, Jeannette Green, Glenn S. Kroog
| Nature Verified
Abstract LINKER-MM1 (NCT03761108) is a Phase 1/2 study of linvoseltamab, a human BCMA×CD3 bispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class exposed (TCE) with ≥ 3 prior lines of therapy (3L+), or triple-class refractory (TCR).
Open in Who Shared Issue with article?

Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody - Leukemia

|
By Marc S. Raab, Yael Cohen, Fredrik Schjesvold, Andrew Spencer, Martin Wermke, Anita Souza, Jonathan Kaufman, Enrique M. Ocio, Kristin Henson, Pierre-Eric Juif, John Blankenship, Serena De Vita
| Nature Verified
Correction to: Leukemia https://doi.org/10.1038/s41375-023-01883-3, published online 06 April 2023 In this article the wrong figure appeared as Fig. 3a; the figure should have appeared as shown below. The original article has been corrected. About this article Raab, M.S., Cohen, Y.C., Schjesvold, F. et al. Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody. Leukemia (2025).
Open in Who Shared Issue with article?

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation | Leukemia

|
By Enrique M. Ocio, Aurore Perrot, Jesus San-Miguel, Jesús F San-Miguel, Sara Bringhen, Maria-Victoria Mateos, Paula Rodríguez-Otero, Stefania Oliva
| Nature Verified
Abstract Patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplantation (ASCT) have lower survival rates and may benefit from frontline regimens that include novel agents. This Phase 1b study (NCT02513186) evaluated preliminary efficacy, safety, and pharmacokinetics (PK) of isatuximab, an anti-CD38 monoclonal antibody, combined with bortezomib-lenalidomide-dexamethasone (Isa-VRd) in patients with NDMM ineligible for/with no intent for immediate ASCT.
Open in Who Shared Issue with article?
See all 5 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified